Analytical Data
-
Gene name
HLA-A*02:01&B2M&MAGE-A4(KVLEHVVRV) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & MAGE-A4 (KVLEHVVRV)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&KVLEHVVRV
-
Molecular Weight
42-45 kDa and 15 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*02:01, a major histocompatibility complex class I molecule, plays a pivotal role in the immune system by presenting peptide antigens to CD8+ T cells, thus facilitating immune responses against tumors and infections. The protein β2-microglobulin (β2M) is essential for the stability and proper functioning of HLA class I molecules. The MAGE-A4 peptide (KVLEHVVRV), derived from the melanoma-associated antigen MAGE-A4, has been identified as a target for immunotherapy due to its ability to elicit strong T cell responses in cancer patients. The study of HLA-A*02:01 in complex with β2M and the MAGE-A4 peptide is crucial for understanding how this specific antigen is presented to T cells. By producing a recombinant monomeric form of this complex, researchers aim to analyze its structural and functional characteristics in detail. This research not only enhances our understanding of T cell recognition and activation but also informs the development of targeted immunotherapies for cancers expressing MAGE-A4. Overall, the investigation of the HLA-A*02:01/β2M/MAGE-A4 complex is instrumental in elucidating the mechanisms of immune recognition and designing effective cancer vaccines or adoptive T cell therapies.
